Hematuria in Patients with Heart Failure – Evidence‑Based Evaluation and Management

Pathophysiology

Cardiorenal syndrome in heart failure produces azotemia, proteinuria, and functional renal impairment but does not cause bleeding into the urinary tract. The mechanisms involve hemodynamic, neurohormonal, and inflammatory pathways without hematuria. 1

Anticoagulation, commonly prescribed for atrial fibrillation (present in >30 % of acute heart‑failure admissions), can precipitate hematuria, especially when underlying renal dysfunction from cardiorenal syndrome is present. The combined effect markedly raises bleeding risk. 4

Urine microscopy is essential to distinguish true hematuria from hemoglobinuria or myoglobinuria; it provides an excellent negative predictive value for genuine tubular injury. Red blood cells on microscopy confirm true hematuria. 1
When evaluating hematuria in heart‑failure patients, clinicians should specifically review current anticoagulation therapy and any recent intensification of loop diuretic regimens. These medication factors are frequent contributors. 4
A focused assessment for infective endocarditis—including fever, new cardiac murmur, and embolic phenomena—should be performed, as endocarditis can cause both cardiac decompensation and glomerulonephritis with hematuria. 3

Guideline‑directed heart‑failure therapies (e.g., ACE inhibitors, ARBs) should not be discontinued solely because hematuria is observed; the underlying cause must be identified first. Maintaining disease‑modifying treatment is critical. 5
Spironolactone may be temporarily withheld during an acute dehydrating illness to mitigate hyper‑kalemia risk, but this adjustment is not intended to prevent hematuria. 3
**Reversible contributors to hematuria should be addressed promptly:

Attributing hematuria to “cardiorenal syndrome” without further investigation can miss treatable etiologies such as endocarditis, nephrolithiasis, or urinary‑tract malignancy. A thorough work‑up is therefore warranted. 1
Discontinuing essential heart‑failure medications based solely on the presence of hematuria can worsen cardiac outcomes; therapy should be maintained unless a clear bleeding source is confirmed. 5